Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action

Noor, Aina Akmal Mohd; Azlan, Maryam; Redzwan, Norhanani Mohd

doi:10.3390/biomedicines10020498

Cited by 27 publications

(17 citation statements)

References 183 publications

(224 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The synergistic effect of the cytokines likely explains most of the features of PsO, such as skin inflammation, hyperkeratinization and increased neovascularisation [ 6 ]. The implementation of new effective biological drugs in the treatment of PsO provides insights into how beneficial it is to block selected immune components, such as cytokines [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Chemokine Profile in Psoriasis Patients in Correlation with Disease Severity and Pruritus

Purzycka-Bohdan

Nedoszytko

Zabłotna

et al. 2022

IJMS

View full text Add to dashboard Cite

Psoriasis (PsO) is a chronic, immune-mediated, inflammatory skin disease associated in most cases with pruritus. Chemokines seem to play a significant role in PsO pathogenesis. The aim of the study was to analyse serum concentrations of CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, CCL17/TARC, CCL18/PARC, CCL22/MDC and CXCL8/IL-8, and their correlation with PsO severity and pruritus intensity. The study included 60 PsO patients and 40 healthy volunteers. Serum concentrations of six (CCL2/MCP-1, CCL3/MIP-1α, CCL5/RANTES, CCL17/TARC, CCL18/PARC and CCL22/MDC) out of eight analysed chemokines were significantly elevated in PsO patients; however, they did not correlate with disease severity. The serum level of CCL5/RANTES was significantly higher in patients with the psoriasis area and severity index (PASI) ≥ 15 (p = 0.01). The serum concentration of CCL17/TARC correlated positively with pruritus assessed using the visual analogue scale (VAS) (R = 0.47; p = 0.05). The study indicated CCL17/TARC as a potential biomarker of pruritus intensity in PsO patients. Chemokines appear to be involved in the development of PsO systemic inflammation. Further detailed studies on the interactions between chemokines, proinflammatory cytokines and immune system cells in PsO are required to search for new targeted therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Chemokine Profile in Psoriasis Patients in Correlation with Disease Severity and Pruritus

Purzycka-Bohdan

Nedoszytko

Zabłotna

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Increased levels of cytokines such as IL-6, IL-10, IL-12, IL-13, and IL-17 were found in individuals with depression [ 35 ]. As such, it stands to reason that biologic therapies, which interrupt the inflammatory cycle, may not only alleviate psoriatic lesions but also diminish the psychological burden [ 36 ]. TNF-a inhibitors are seemingly the most effective in this regard.…”

Section: Discussionmentioning

confidence: 99%

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients

Beni

Mocan

Florian

et al. 2023

Life

View full text Add to dashboard Cite

Background: Psoriasis is an immune-mediated chronic skin disease that is associated with a significant psychological burden. A newer line of therapy is represented by biologic agents. Our study aimed to evaluate the effect of biologic therapies in the treatment of psoriasis concerning both disease severity and psychological comorbidity. Material and Methods: We performed a prospective case-control comparison to evaluate the prevalence of depression and anxiety in psoriasis patients and unaffected individuals. All patients were recruited between October 2017 and February 2021. Baseline depression (PHQ-9), anxiety (GAD-7), PASI, and DLQI scores were noted. Then, we evaluated the efficacy of biologic treatment in reducing these scores at 6 months of therapy. Patients were treated with either ixekizumab, secukinumab, guselkumab, certolizumab, ustekinumab, risankizumab, or adalimumab. Results: 106 bio-naïve patients with psoriasis and 106 controls without the disease were included in this study. Depression and anxiety were significantly more common among psoriasis patients than in unaffected individuals (p < 0.0001). Female patients presented both depression and anxiety more frequently than men in both case and control groups. Disease severity was significantly associated with worsened depression and anxiety symptoms. Biologic therapy resulted in a significant decrease in all four scores at the 6-month mark for each patient (p < 0.0001). Only an improved PASI correlated significantly with lower depression and anxiety scores (p < 0.005), whereas a decreased DLQI did not (p > 0.955). None of the seven biologic agents used was discovered to be superior. Conclusion: biologic therapies are effective in decreasing both disease severity and alleviating depression and anxiety symptoms in psoriasis.

show abstract

“…Moreover, nucleic acid complexes, such as AMPs including DEFB4 within the upper layer of the skin, stimulate plasmacytoid dendritic cells during the onset of psoriasis. Plasmacytoid DCs produce cytokines such as IFN‐γ, TNF‐α and IL‐23 to interact with myeloid dendritic cells, leading to clonal expansion of Th17 cells which produce IL‐17 and IL‐22 51 . These suggest the following: Reduced KPRP expression in keratinocytes might bring the reduced expression of antimicrobial peptides, thereby reducing the proliferation of IL‐17‐producing cells in the psoriatic skin inflammation.…”

Section: Discussionmentioning

confidence: 99%

Keratinocyte proline‐rich protein modulates immune and epidermal response in imiquimod‐induced psoriatic skin inflammation

Matsuno,

Sumida,

Nakanishi

et al. 2023

Experimental Dermatology

View full text Add to dashboard Cite

Psoriasis is a persistent inflammatory skin disease thought to arise as a result of the infiltration of inflammatory cells and activation of keratinocytes. Recent advances in basic research and clinical experience revealed that the interleukin (IL)‐23/IL‐17 axis has been identified as a major immune pathway in psoriasis. However, it remains unclear how keratinocyte factors contribute to the pathology of psoriasis. Keratinocyte proline‐rich protein (KPRP) is a proline‐rich insoluble protein, which is present in the epidermis and is likely to be involved in the skin barrier function. Here, to investigate the potential roles of KPRP in psoriatic skin inflammation, Kprp‐modified mice were applied in the imiquimod (IMQ)‐induced skin inflammation model, which develops psoriasis‐like epidermal hyperplasia and cutaneous inflammation features. Then, heterozygous knockout (Kprp+/−) but not homozygous knockout (Kprp−/−) mice displayed attenuated skin erythema compared to control wild‐type mice. In addition, RNA sequencing, quantitative PCR and/or histological analysis detected changes in the expression of several molecules related to psoriatic inflammation or keratinocyte differentiation in Kprp+/− mice, but not Kprp−/− mice. Further analysis exhibited reduced IL‐17‐producing γδlow T cells and amplified epidermal hyperplasia in Kprp+/− mice, which were implied to be related to decreased expression of β‐defensins and increased expression of LPAR1 (Lysophosphatidic acid receptor 1), respectively. Thus, our results imply that KPRP has the potential as a therapeutic target in psoriatic skin inflammation.

show abstract

Orchestrated Cytokines Mediated by Biologics in Psoriasis and Its Mechanisms of Action

Cited by 27 publications

References 183 publications

Chemokine Profile in Psoriasis Patients in Correlation with Disease Severity and Pruritus

Chemokine Profile in Psoriasis Patients in Correlation with Disease Severity and Pruritus

Biologic Therapies Decrease Disease Severity and Improve Depression and Anxiety Symptoms in Psoriasis Patients

Keratinocyte proline‐rich protein modulates immune and epidermal response in imiquimod‐induced psoriatic skin inflammation

Contact Info

Product

Resources

About